VANCOUVER, BC, April 8, 2021 /CNW/ - Rakovina Therapeutics Inc. (the "Company") (TSXV: RKV) today announced that the Company has been granted patents entitled "Tricyclic Inhibitors of Poly(ADP-Ribose) Polymerase" by the European and Canadian Patent Offices.
The granted patent claims cover the composition of matter and uses of drug candidates from Rakovina Therapeutics' kt-2000 series, one of three novel series of DNA-damage response inhibitors being researched by the Company as potential targeted cancer therapies under a collaborative research agreement with the University of British Columbia.
"With our focus on the rapid progress of our research programs, we are pleased to receive these patent allowances in Europe and Canada," said Prof. Mads Daugaard, Rakovina Therapeutics' president and chief scientific officer. "These patents further establish our strong global intellectual property protection and provide patent claims in Canada and the European Union into 2032, supporting our commitment to optimize drug candidates from the kt-2000 series for advancement toward the initiation of human clinical trials."
About Rakovina's kt-2000 Series Drug Candidates
Rakovina Therapeutics' kt-2000 series drug candidates are oral targeted small molecule inhibitors of poly (ADP-ribose) polymerase (PARP). Established data demonstrate that lead candidates from Rakovina Therapeutics' kt-2000 series exhibit potency comparable to FDA-approved PARP-inhibitors and potent anti-cancer activity in preclinical animal models. kt-2000 series lead candidates are being optimized around several differentiating factors and potential competitive advantages.
About Rakovina Therapeutics Inc.
Rakovina Therapeutics Inc. was established in 2020 to develop new cancer treatments based on novel DNA-damage response technologies. The Company has established a pipeline of DNA-damage response inhibitors with the goal of advancing one or more drug candidates into human clinical trials and obtaining marketing approval for new cancer therapeutics from Health Canada, the United States Food and Drug Administration and similar international regulatory agencies. Further information may be found at www.rakovinatherapeutics.com.
The TSXV has neither approved nor disapproved the content of this press release. Neither the TSXV nor its Regulation Services Provider (as that term is defined in policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.
Notice regarding forward-looking statements:
This release includes forward-looking statements regarding the Company and its respective business, which may include, but is not limited to, statements with respect to the proposed business plan of the Company and other statements. Often, but not always, forward-looking statements can be identified by the use of words such as "plans", "is expected", "expects", "scheduled", "intends", "contemplates", "anticipates", "believes", "proposes" or variations (including negative variations) of such words and phrases, or state that certain actions, events, or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Such statements are based on the current expectations of the management of the Company. The forward-looking events and circumstances discussed in this release may not occur by certain specified dates or at all and could differ materially as a result of known and unknown risk factors and uncertainties affecting the Company, including risks regarding the medical device industry, economic factors, regulatory factors, the equity markets generally and risks associated with growth and competition. Although the Company has attempted to identify important factors that could cause actual actions, events, or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events, or results to differ from those anticipated, estimated or intended. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and the Company undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise. The reader is referred to the Company's most recent filings on SEDAR for a more complete discussion of all applicable risk factors and their potential effects, copies of which may be accessed through the Company's profile page at www.sedar.com.
For further information: Rakovina Therapeutics Inc., David Hyman, Chief Financial Officer, Email: email@example.com; Investor Relations Contact, IR@rakovinatherapeutics.com; Media Contact, MEDIA@rakovinatherapeutics.com